How do you spell dilution? ESS is an actual product that will see patients. Now, it should not sell for $250000 a treatment but well, you never know. 2000 patients a year will bring in some revenue at some point.
So, I would buy more on the Lympro data dip and then accumulate.
IF they study MANF they MUST get JVs so since they are going to study MANF, they will get JVs.
As noted previously, they WILL be giving away the future there, it just depends on how much of the company possible revenue they give away. If I were Pharma, and I knew this was their first JV, and this is their only way to success, I would squeeze.
News 
Market Data 
Discover 
